Reduced dose pentostatin for initial management of hairy cell leukemia patients who have active infection or risk of hemorrhage is safe and effective

Haematologica. 2015 Jan;100(1):e18-20. doi: 10.3324/haematol.2014.113290. Epub 2014 Oct 31.

Authors

Leslie A Andritsos¹, Neil Dunavin², Gerard Lozanski³, Jeffrey A Jones⁴, James S Blachly⁴, David M Lucas⁴, John C Byrd⁴, Eric Kraut⁴, Michael R Grever⁴

Affiliations

¹ The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH leslie.andritsos@osumc.edu.
² National Institutes of Health, National Heart, Lung, and Blood Institute, Hematology Branch, Bethesda, MD.
³ The Ohio State University, Department of Pathology, Columbus, OH, USA.
⁴ The Ohio State University, Department of Internal Medicine, Division of Hematology, Columbus, OH.

No abstract available

Keywords: hairy cell leukemia; pentostatin.

Publication types

Letter

MeSH terms

Adult
Aged
Antineoplastic Agents / therapeutic use*
Disease Management
Dose-Response Relationship, Drug
Female
Follow-Up Studies
Hemorrhage / complications
Hemorrhage / drug therapy*
Humans
Infections / complications
Infections / drug therapy*
Leukemia, Hairy Cell / drug therapy*
Leukemia, Hairy Cell / pathology
Male
Middle Aged
Neoplasm Staging
Pentostatin / therapeutic use*
Prognosis
Remission Induction

Substances

Antineoplastic Agents
Pentostatin